BRAF mutation in papillary thyroid carcinoma

被引：1

作者：

Li, Xinying ^{[1
,2
]}

Abdel-Mageed, Asim B. ^{[3
]}

Kandil, Emad ^{[1
,3
]}

机构：

[1] Tulane Univ, Sch Med, Dept Surg, New Orleans, LA 70112 USA

[2] Cent S Univ, Xiangya Hosp, Dept Gen Surg, Changsha, Hunan, Peoples R China

[3] Tulane Univ, Sch Med, Tulane Canc Ctr, Dept Pharmacol, New Orleans, LA 70112 USA

来源：

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2012年 / 5卷 / 04期

关键词：

BRAF mutation; papillary thyroid carcinoma; BRAF/MAPK signaling pathway; targeting therapy; KAPPA-B ACTIVATION; BRAF(V600E) MUTATION; GENE-EXPRESSION; V600E MUTATION; CANCER CELLS; MANAGEMENT; RAF; ASSOCIATION; RECURRENCE; DIAGNOSIS;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

BRAF mutation is the most common genetic alternation in thyroid cancer, particularly in papillary thyroid cancer (PTC). Excessive activation of BRAF/MAPK signaling pathway due to BRAF mutation plays a central role in the tumorigenesis and development of PTC. The association of BRAF mutation with poor clinicopathological characteristics of PTC further demonstrated the importance of the BRAF mutation alternation in PTC. Detection of BRAF mutation on FNA specimen before surgery is recommended as a useful diagnostic marker and prognostic indicator for PTC, and thus influences surgeon's decision on management of PTC. Recent studies have focused on inhibition of BRAF activation and several small molecules have been developed as targeting therapy.

引用

页码：310 / 315

页数：6

共 34 条

[1] Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: A Synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference [J].

Baloch, Zubair W. ;

LiVolsi, Virginia A. ;

Asa, Syl L. ;

Rosai, Juan ;

Merino, Maria J. ;

Randolph, Gregory ;

Vielh, Philippe ;

DeMay, Richard M. ;

Sidawy, Mary K. ;

Frable, William J. .

DIAGNOSTIC CYTOPATHOLOGY, 2008, 36 (06) :425-437

[2] BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy [J].

Bommarito, Alessandra ;

Richiusa, Pierina ;

Carissimi, Elvira ;

Pizzolanti, Giuseppe ;

Rodolico, Vito ;

Zito, Giovanni ;

Criscimanna, Angela ;

Di Blasi, Francesco ;

Pitrone, Maria ;

Zerilli, Monica ;

Amato, Marco C. ;

Spinelli, Gaetano ;

Carina, Valeria ;

Modica, Giuseppe ;

Latteri, M. Adelfio ;

Galluzzo, Aldo ;

Giordano, Carla .

[3] Increasing incidence of thyroid cancer in the United States, 1973-2002 [J].

Davies, L ;

Welch, HG .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (18) :2164-2167

[4] BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism [J].

Durante, C. ;

Puxeddu, E. ;

Ferretti, E. ;

Morisi, R. ;

Moretti, S. ;

Bruno, R. ;

Barbi, F. ;

Avenia, N. ;

Scipioni, A. ;

Verrienti, A. ;

Tosi, E. ;

Cavaliere, A. ;

Gulino, A. ;

Filetti, S. ;

Russo, D. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (07) :2840-2843

[5] BRAF(V600E) mutation and the biology of papillary thyroid cancer [J].

Frasca, F. ;

Nucera, C. ;

Pellegriti, G. ;

Gangemi, P. ;

Attard, M. ;

Stella, M. ;

Loda, M. ;

Vella, V. ;

Giordano, C. ;

Trimarchi, F. ;

Mazzon, E. ;

Belfiore, A. ;

Vigneri, R. .

[6] Molecular classification of papillary thyroid carcinoma:: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis [J].

Giordano, TJ ;

Kuick, R ;

Thomas, DG ;

Misek, DE ;

Vinco, M ;

Sanders, D ;

Zhu, ZW ;

Ciampi, R ;

Roh, M ;

Shedden, K ;

Gauger, P ;

Doherty, G ;

Thompson, NW ;

Hanash, S ;

Koenig, RJ ;

Nikiforov, YE .

ONCOGENE, 2005, 24 (44) :6646-6656

[7] Phase II trial of sorafenib in advanced thyroid cancer [J].

Gupta-Abramson, Vandana ;

Troxel, Andrea B. ;

Nellore, Anoma ;

Puttaswamy, Kanchan ;

Redlinger, Maryann ;

Ransone, Kathy ;

Mandel, Susan J. ;

Flaherty, Keith T. ;

Loevner, Laurie A. ;

O'Dwyer, Peter J. ;

Brose, Marcia S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4714-4719

[8] Both BRAF V600E Mutation and Older Age (≥65 Years) are Associated with Recurrent Papillary Thyroid Cancer [J].

Howell, Gina M. ;

Carty, Sally E. ;

Armstrong, Michaele J. ;

LeBeau, Shane O. ;

Hodak, Steven P. ;

Coyne, Christopher ;

Stang, Michael T. ;

McCoy, Kelly L. ;

Nikiforova, Marina N. ;

Nikiforov, Yuri E. ;

Yip, Linwah .

ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (13) :3566-3571

[9] Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer [J].

Hu, Shuiying ;

Liu, Dingxie ;

Tufano, Ralph P. ;

Carson, Kathryn A. ;

Rosenbaum, Eli ;

Cohen, Yoram ;

Holt, Elizabeth H. ;

Kiseljak-Vassiliades, Katja ;

Rhoden, Kerry J. ;

Tolaney, Sara ;

Condouris, Stephen ;

Tallini, Giovanni ;

Westra, William H. ;

Umbricht, Christopher B. ;

Zeiger, Martha A. ;

Califano, Joseph A. ;

Vasko, Vasily ;

Xing, Mingzhao .

INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (10) :2322-2329

[10] The prevalence and prognostic value of BRAF mutation in thyroid cancer [J].

Kebebew, Electron ;

Weng, Julie ;

Bauer, Juergen ;

Ranvier, Gustavo ;

Clark, Orlo H. ;

Duh, Quan-Yang ;

Shibru, Daniel ;

Bastian, Boris ;

Griffin, Ann .

ANNALS OF SURGERY, 2007, 246 (03) :466-471

← 1 2 3 4 →